G17DT Immunogen is a vaccine that neutralizes gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for... It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine.
- Mechanism
- Curator reviewed
When administered, G17DT induces an immune response producing antibodies which bind with the peptide and also cross-react and neutralise gastrin 17 thus inhibiting the growth of gastrointestinal cancers and metastasis. In addition the product neutralizes glycine-extended gastrin 17 which is also a stomach and pancreatic cancer growth factor.
- Primary indication
- Intended for the treatment of various forms of cancer.Curator reviewed
- Also known as
- Anti-gastrin 17 immunogen · Antigastrin 17 · G17DT · G17DT (AN ANTIGASTRIN IMMUNOGEN) · GASTRIMMUNE
Resolves to
What you can answer from here — as of October 01, 2026
Which companies are running trials of G17DT Immunogen, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account